Valuation: Phosphagenics Limited

Market Cap 8.04Cr 5.63Cr 4.94Cr 4.59Cr 4.22Cr 7.92Cr 541.71Cr 55Cr 21Cr 266.32Cr 21Cr 21Cr 920.81Cr P/E 2024
-2.5x
P/E 2025 -6.43x
Enterprise Value 7.58Cr 5.3Cr 4.66Cr 4.33Cr 3.97Cr 7.46Cr 510.4Cr 51Cr 20Cr 250.93Cr 20Cr 19Cr 867.59Cr EV / Sales 2024
5.85x
EV / Sales 2025 23x
Free-Float
76.76%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 01/05/2020
Chief Operating Officer - 01/05/2020
Corporate Secretary - 01/05/2026
Director TitleAgeSince
Director/Board Member - 13/04/2015
Chairman - 01/01/2019
Director/Board Member 59 26/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
-14.29%-14.29% - - 5.63Cr
+0.86%+1.43%+48.50%+160.39% 1,06700Cr
+1.59%+4.09%+55.34%+53.96% 63TCr
+0.95%+1.91%+35.91%+81.14% 46TCr
+1.60%+6.25%+33.95%+29.84% 35TCr
-0.60%+1.52%+35.68%+39.76% 30TCr
-0.14%+0.60%+16.17%+17.53% 26TCr
+0.09%-2.82%-28.29%-41.71% 22TCr
+1.22%+2.66%+21.87%+59.73% 20TCr
-1.18%-3.70%+14.23%+66.51% 16TCr
Average -1.10%+1.33%+25.93%+51.91% 40.48TCr
Weighted average by Cap. +0.55%+1.95%+35.81%+77.68%

Financials

2024 2025
Net sales 11.33L 8L 7L 6L 6L 11.15L 7.63Cr 76.83L 30.02L 3.75Cr 29.73L 29.09L 13Cr 12.38L 9L 8L 7L 6L 12.19L 8.34Cr 83.95L 32.8L 4.1Cr 32.49L 31.79L 14Cr
Net income -31.22L -21.83L -19.18L -17.83L -16.36L -30.75L -21Cr -2.12Cr -82.73L -10Cr -81.96L -80.19L -36Cr -44.17L -30.89L -27.13L -25.23L -23.15L -43.5L -30Cr -3Cr -1.17Cr -15Cr -1.16Cr -1.13Cr -51Cr
Net Debt -12.98L -9L -8L -7L -7L -12.78L -8.74Cr -88.03L -34.39L -4.3Cr -34.07L -33.34L -15Cr -46.49L -32.51L -28.55L -26.55L -24.37L -45.78L -31Cr -3.15Cr -1.23Cr -15Cr -1.22Cr -1.19Cr -53Cr
Logo Phosphagenics Limited
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using proprietary and patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol, Veterinary Applications, among others. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Employees
-